Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $182.50 short put and a strike $177.50 long put offers a potential 29.2% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $182.50 by expiration. The full premium credit of $1.13 would be kept by the premium seller. The risk of $3.87 would be incurred if the stock dropped below the $177.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 78.55 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Rivals Unlikely to Knock Allergan's Botox Off its Perch: Analyst
Mon, 29 Jan 2018 22:58:00 +0000
Barclays analyst Douglas Tsao expects Botox to remain the market leader.
Is Allergan plc (NYSE:AGN) Undervalued?
Mon, 29 Jan 2018 20:02:34 +0000
Today we’re going to take a look at the well-established Allergan plc (NYSE:AGN). The company’s stock saw a double-digit share price rise of over 10% in the past couple ofRead More…
Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved
Mon, 29 Jan 2018 15:39:07 +0000
Allergan plc Ordinary Shares (NYSE: AGN ) is down 26 percent over the last six months, but one analyst said there's only upside to its sickly state. The biotech’s trajectory inspired an upgrade from a …
Pernix Therapeutics Holdings Inc Reaches Settlement in Zohydro Patent Litigation
Mon, 29 Jan 2018 15:00:27 +0000
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that it has entered into a settlement agreement with Actavis Laboratories FL (“Actavis”) resolving patent litigation related to Zohydro® ER (hydrocodone bitartrate). The litigation has been pending in the U.S. District Court for the District of Delaware and resulted from Actavis’s submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food & Drug Administration (FDA) seeking approval to market a generic version of Zohydro® ER.
Pfizer’s 4Q17 Estimates: Products with Lower Sales
Fri, 26 Jan 2018 14:02:57 +0000
What to Expect from Pfizer’s 4Q17 Earnings on January 30
Also on Market Tamer…
Follow Us on Facebook